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103 PREDICTIVE RELATIONSHIP OF SERUM MARKERS OF
CARTILAGE METABOLISM TO IMAGING AND CLINICAL
OUTCOME MEASURES OF JOINT INTEGRITY
P.A. Berry1, R.A. Maciewicz2, A.E. Wluka1, M.D. Downey-Jones2,
E.A. Mills2, C.J. Oakley2, F.M. Cicuttini1. 1Monash University,
Melbourne, AUSTRALIA, 2AstraZeneca, Macclesﬁeld, UNITED
KINGDOM
Purpose: Osteoarthritis (OA) is a heterogenous disease with outcomes
of pain and joint disability and often results in joint replacement, and is
on the incline due to an aging population and the adiposity epidemic.
This personal, societal and economic burden could be reduced with
better predictors of disease progression. This study aimed to examine
whether serum markers of cartilage metabolism provide a consistent
prediction model for change in cartilage quantity and integrity, and to
determine whether these markers relate to knee joint replacement, a
clinically relevant outcome.
Methods: Change in cartilage volume and defects over 2 years were
measured in a convenience group of 117 subjects with symptomatic and
radiographic knee OA using MRI. At 4-year follow-up, subjects were asked
whether they had undergone knee joint replacement. The relationships
between these cartilage changes, and odds of knee joint replacement with
baseline levels of serum markers of cartilage metabolism (N-propeptide
of type IIa procollagen (PIIANP), type II collagen breakdown product
(C2C), cartilage oligomeric matrix protein (COMP)) individually, and as
a ratio (PIIANP:C2C), were examined using multiple regression analysis
adjusted for age, gender and BMI.
Results: Higher level of PIIANP was associated with reduced medial
cartilage volume loss (p = 0.05) and reduced odds of knee joint replace-
ment at 4 years (p = 0.04) after adjustment for potential confounders.
Similar results were obtained when the ratio of PIIANP (synthesis) to
C2C (degradation) were considered i.e.. Higher levels of COMP were
associated with reduced medial cartilage volume loss (p = 0.02) and
increased medial tibiofemoral cartilage defect severity (p = 0.04).
Conclusions: The results of this study suggest that markers of cartilage
metabolism either individually or as a ratio, may be used to identify OA
patients who are likely to suffer a loss of cartilage volume or increase in
cartilage defect as deﬁned by MRI and in the longer-term require joint
replacement. Providing appropriate treatment to this patient group may
with time reduce the overall burden of this disease.
104 AN ASSOCIATION BETWEEN SERUM BIOMARKER LEVELS
AND STRUCTURAL PROGRESSION IN MEDIAL KNEE
OSTEOARTHRITIS
B. Goker1, M.D. Demirag1, E.J. Thonar2, J.A. Block2. 1Gazi University,
Ankara, TURKEY, 2Rush University Medical Center, Chicago, IL, USA
Purpose: Antigenic keratan sulfate (agKS) and hyaluronic acid (HA)
have each been studied as putative biomarkers to assess joint disease.
Whereas agKS in serum is thought to reﬂect cartilage metabolism, HA
is generally related to systemic inﬂammation. As part of a long-term
controlled trial of the biomechanical effects of wedged orthotic shoe
inserts in medial compartment OA, biomarkers were monitored. Here,
we assess the relationship of agKS and HA in serum to structural
progression, using radiographic joint space narrowing (JSN) as a marker
of progression.
Methods: 100 subjects (Kellgren-Lawrence grade 2−3, pain on ambu-
lation >30mm on a 100mm visual analog scale) were enrolled into a
36 month randomized controlled trial of orthotic wedges vs neutral orthotic
inserts in medial knee OA. Serum for biomarkers was analyzed in 47
randomly selected subjects, 27 from the wedge group and 20 from the
neutral group; 16 were males, 31 were females, mean age 59±10 years.
Subjects underwent semi-ﬂexed ﬂuoroscopic-guided PA knee radiography
(Schuss view) at entry and at 36 months, and the medial compartment
JSWs were quantiﬁed using Image J software (US NIH, Bethesda, MD,
http://rsb.info.nih.gov/ij/). Serum levels of baseline and 12-month agKS
and HA were determined by ELISA. p< 0.05 was considered signiﬁcant
in the statistical analysis.
Results: Baseline levels did not differ between the wedge and the neu-
tral orthotics groups for either HA (48.67±28.91 vs 68.15±56.56 ng/ml,
respectively, t-test p = 0.13, respectively) or agKS (363.22±129.60 vs
360.60±125.08, t-test p = 0.95), nor was there signiﬁcant change at 12
mos for either group (p> 0.05 for all variables). The medial compart-
ment JSW of the index knees at baseline in the wedge and control
groups were 3.22±1.58 and 3.32±1.72mm, respectively (p = 0.76), and at
36 months, the decline in JSWs were −0.057±1.13 and 0.271±0.427mm,
respectively (p = 0.31). Of the 47 patients who had baseline serum levels
determined, 32 patients completed the 36-month study and were included
in the correlation analyses. Although group biomarker differences were
not signiﬁcant, the baseline serum agKS level was signiﬁcantly negatively
correlated with the rate of joint space narrowing (JSN) over 36 months
(Pearson’s r = −0.41, p = 0.021). Similarly, the change in agKS during the
ﬁrst 12 months was negatively correlated with JSN (Pearson’s r = −0.40,
p = 0.033). In contrast, neither the baseline HA level nor the change in
HA during 12 months correlated with the rate of JSN (r = −0.13, p = 0.5
and r = 0.056, p = 0.97, respectively).
Conclusions: These data suggest that the structural progression in OA is
unrelated to HA levels, which may imply that the inﬂammatory component
in OA is less important to progression of JSN than in the systemic
inﬂammatory diseases. However, structural progression in OA appears
to be negatively related to serum agKS. As agKS is considered a marker
of cartilage metabolism, the ﬁnding of a negative relationship between
agKS levels (and change over time) with OA structural progression may
suggest that individuals with more metabolically active cartilage are better
able to resist the degenerative processes of OA.
105 A NOVEL MODEL SYSTEM FOR DRUG DISCOVERY
IN OSTEOARTHRITIS: MONITORING WHOLE TISSUE
TURNOVER IN MURINE FEMUR HEADS
S.H. Madsen, K. Henriksen, N. Schultz, G. Thomsen, A.V. Neutzsky-
Wulff, M.A. Karsdal. Nordic Bioscience, Herlev, DENMARK
Purpose: The pathophysiology of osteoarthritis (OA) comprises the
whole joint. OA is characterized by chondrocyte hypertrophy, cartilage
degradation and altered subchondral bone resulting from changes in
osteoclastic bone resorption and osteoblastic bone formation. At present
there are neither biological models nor tools that allow investigation of the
interactions between osteoblasts, osteoclasts and chondrocytes. Thus,
we developed a femur head model, which will allow for investigate whole
tissue pathology. This will aid to identify novel molecules and targets,
which will affect the whole joint, as thereby hopefully identify candidates
for drug development within osteoarthritis.
Methods: Femur heads from three week old mice were isolated and
cultured for 10 days in DMEM:F12 containing IGF-I [100 nM], PTH
[100 nM], RANKL [100 ng/ml], Il-1a [10 ng/ml], OSM [10 ng/ml] + TNF-a
[20 ng/ml], OSM [10 ng/ml] + TNF-a [20 ng/ml] + GM6001 [10mM] and
GM6001 [10mM] alone. The conditioned medium was kept for analy-
sis of biochemical markers of bone and cartilage turnover, including
CTX-I (bone resorption), CTX-II (cartilage degradation), PIINP (cartilage
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formation), TRACP (osteoclast number), and GAG release (cartilage
turnover). Overall cell viability was monitored using the dye Alamar Blue.
Passive release from metabolically inactive femur heads was measured
as background.
Results: Stimulation of the femur heads with RANKL, PTH, Il-1a and
OSM + TNF-a led to an increase in CTX-I release. Adding GM6001 to
OSM + TNF-a abrogated the release of CTX-I. Femur heads stimulated
with Il-1a, OSM + TNF-a and OSM + TNF-a + GM6001 induced an
increase in sGAG release. CTX-II release was increased by RANKL, PTH,
Il-1a, OSM + TNF-a and IGF-I. CTX-II release from the OSM + TNF-
a condition was abrogated when treated with GM6001. The osteoclast
marker TRACP increased when stimulated by RANKL, PTH, Il-1a, OSM +
TNF-a, OSM + TNF-a + GM6001. PIINP release was reduced when
stimulating with Il-1a, OSM + TNF-a, OSM + TNF-a + GM6001, whereas
PTH and IGF-I increased PIINP release.
Conclusions: We have established a whole tissue model for osteoarthri-
tis consisting of both cartilage and bone, and which is highly responsive
to both catabolic and anabolic stimulation. This is useful for testing
potential treatments for OA interfering with more than one aspect of
the pathological situation. Further it allows for investigating interactions
between cartilage and bone cell types.
Hopefully, future treatments for OA may be better identiﬁed after the
establishment of such a system for drug screening.
106 LOCALIZATION OF MMP- AND AGGRECANASE-GENERATED
NEO-EPITOPES IN OA ARTICULAR CARTILAGE
A-C. Bay-Jensen1, B. Wang2, C. Christiansen1, J. Wang2, Q. Zheng2,
M.A. Karsdal1, P. Qvist1. 1Nordic Bioscience A/S, Herlev, DENMARK,
2Nordic Bioscience A/S, Beijing, CHINA
Purpose: MMP- and aggrecanase-mediated degradation of the cartilage
matrix, and aggrecan in particular, have been extensively studied in
cartilage explants as these two families of proteases are the most impor-
tant proteolytic enzymes involved in cartilage turnover. Catabolic stimu-
lated bovine explants cultures have been reported to release aggrecan-
fragments carrying aggrecanase-mediated neo-epitopes (e.g. the amino
acid sequence 374ARGSV. . . ) in the early phases, while the release
into the supernatant of fragments expressing the MMP-mediated neo-
epitopes (such as 342FFGVG. . . ) is delayed until the later stages. We
therefore wanted to investigate if this separation in time was reﬂected
in the differential localization of the aggrecan fragments in the cartilage
tissue. The overall aim of the study was to determine the localization of
aggrecan-related neo-epitopes in human sections of articular cartilage.
Methods: Human OA articular cartilage was obtained from knee replace-
ment surgery. Full depth biopsies were isolated from areas proximal
to lesions, followed by ﬁxing in paraformaldehyde, decalciﬁcation and
parafﬁn embedding. Sequential cartilage section were immunohistochem-
ically stained for presence of MMP and aggrecanase-mediated neo-
epitopes using monoclonal antibody AF28, BC-3 and 1H11 recognizing
the 342FFGVG. . . , the 374ARGSV. . . and the NITEGE373, respectively.
Results: IHC staining of the cartilage sections aggrecanase-mediated
aggrecan fragments in the proximity of the chondrocytes in the upper
zones. However, aggrecan fragments generated by aggrecanases – BC-3
and 1H11 – were found at the interface between the upper zone and the
superﬁcial layer. Since the superﬁcial layer is still present at this part
of the biopsies (low degree of erosion) it could depict the presence
of aggrecanases-mediated fragments at earlier stages of disease. In
contrast, MMP-mediated fragments were mainly observed in the upper-
mid zone where the superﬁcial layer was lost (high degree of erosion),
speciﬁcally in the surrounding of clusters.
Conclusions: Our immunehistochemistry results support earlier reports,
that the release of aggrecan fragments into the supernatant of the
catabolic stimulated explants cultures showed a bi-phasic pattern with
aggrecanase-mediated release at early time points and MMP-mediated
release of aggrecan fragments at the later stages. We speculate that
MMP and aggrecanases activity is related to disease states more than to
speciﬁc sites. Furthermore that MMP-mediated degradation is related to
areas with high cellular activity (e.g. clusters). The molecular mechanism
and sequence of events is still unclear, but current study gives some
direction to which path to follow.
107 WHOLE BLOOD LEAD (Pb) LEVELS AND PUTATIVE
OSTEOARTHRITIS BIOMARKERS IN AFRICAN AMERICAN
AND CAUCASIAN MEN: THE JOHNSTON COUNTY
OSTEOARTHRITIS PROJECT
J.M. Jordan1, F. Fang2, C. Brooks3, J.B. Renner1, T. Stabler4,
V.B. Kraus4. 1University of North Carolina School of Medicine, Chapel
Hill, NC, USA, 2StatWorks, Inc., RTP, NC, USA, 3Brevard College,
Brevard, NC, USA, 4Duke University Medical Center, Durham, NC, USA
Purpose: Lead (Pb) is a heavy metal that affects many aspects of
bone including osteoclasts, osteoblasts, and calcium and vitamin D
metabolism, and may have effects on cartilage as well. We have reported
associations between whole blood Pb levels and radiographic OA severity
in men and women, and with selected OA biomarkers in women. The
purpose of this analysis was to examine associations between putative
OA biomarkers and blood Pb levels in African American and white men.
Methods: A total of 333 men in the Johnston County OA Project Met-
als Exposure Sub-study (mean age 64.8 (10.7) years, 38.4% African
American) had available demographic and clinical data and whole blood,
serum, or urine samples for whole blood Pb and biomarkers assessments.
Whole blood Pb was measured by inductively coupled plasma mass
spectrometry at the Inorganic Toxicology laboratory, Division of Labora-
tory Sciences, National Center for Environmental Health, CDC, Atlanta,
Georgia. Urine C-telopeptide fragments of type II collagen (CTX-II), cross
linked N telopeptide of type I collagen (NTX-I), serum hyaluronic acid
(HA), cartilage oligometric matrix protein (COMP), and type II procollagen
(CPII) were measured by commercially available kits. Natural logarithm
(ln) transformation was used to produce distributions close to normality
for blood Pb and biomarkers. Spearman correlation coefﬁcients were
calculated between ln Pb and ln of each biomarker. Analysis of covariance
models were used to examine associations between blood Pb levels and
the 5 chosen biomarkers with ln transformed biomarkers as outcomes,
adjusting for age, race, and BMI. Effect modiﬁcation between ln Pb
and race were examined, with signiﬁcance deﬁned by p-values <0.1 for
interaction terms.
Results: Median Pb levels were 2.2 ug/dL (0.5−25.1) and were higher in
African American men than white men (p< 0.0001). In bivariate associa-
tions, ln Pb was correlated with ln CTX-II (r = 0.12, p = 0.035) and ln COMP
(r = 0.20, p< 0.0002), but not with ln NTX-I, ln HA, or ln CPII (r = 0.02,
0.0008, and 0.13, respectively, p> 0.13). In adjusted models, ln Pb was
associated with mean ln CTX-II (p = 0.024) and COMP (p=0.0001). There
were no notable race and ln Pb interactions.
Conclusions: Mean blood Pb levels were associated with urine CTX-II
and serum COMP, but not serum HA or CPII in both African American
and white men. These data suggest that Pb may have an effect on type II
collagen and non-collagenous matrix proteins. Potential effects of Pb in
the pathogenesis of OA, then, are likely to be related to alterations in
these factors, but less likely to effects on synovial inﬂammation.
108 AUROTHIOMALATE INHIBITS COX-2 EXPRESSION AND
PGE2 PRODUCTION IN CHONDROCYTES BY INCREASING
MKP-1 EXPRESSION AND DECREASING p38 AND JNK
PHOSPHORYLATION
R. Nieminen, R. Korhonen, E. Moilanen. Medical School, University of
Tampere, FINLAND
Purpose: Disease-modifying anti-rheumatic drugs (DMARDs) suppress
inﬂammation, and retard cartilage degradation and bone erosion in arthri-
tis. The molecular mechanisms of action of many traditional DMARDs are
not known in detail. Inducible prostaglandin synthase (cyclooxygenase-2,
COX-2) is highly expressed in OA and RA cartilage and it produces
high amounts of proinﬂammatory prostanoids in the joint. The signaling
mechanisms involved in the up-regulation of COX-2 in chondrocytes are
not known in detail. In the present study we investigated the effects
of DMARDs on mitogen-activated protein kinase (MAPK) pathways and
MAP kinase phosphatase-1 (MKP-1) in immortalized H4 chondrocytes*.
Methods: PGE2 production was measured by RIA, protein expression
was measured by Western blot and mRNA expression was measured by
quantitative PCR.
Results:We investigated the effects of traditional DMARDs on MKP-1 ex-
pression in chondrocytes. Unlike the other tested compounds (cyclosporin
A, hydroxychloroquine, leﬂunomide, its active metabolite A771726,
methotrexate and sulfasalazine), aurothiomalate was found to enhance
MKP-1 expression. Aurothiomalate inhibited Il-1b-induced COX-2 expres-
sion and prostaglandin E2 (PGE2) production by destabilizing COX-2
mRNA as did p38 MAPK inhibitor SB203580. Interestingly, aurothiomalate
